诺瓦瓦克斯的实验性新冠-流感联合疫苗在三期试验中显示出老年人群的免疫反应-动脉网

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

benzinga 等信源发布 2025-06-11 11:12



可切换为仅中文







Novavax, Inc.

诺瓦瓦克斯医药公司

NVAX

诺瓦瓦克斯医药

announced results Wednesday of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal

周三公布了其新冠-流感联合疫苗（CIC）和独立的三价血凝素纳米颗粒季节性疫苗初步队列的结果。

influenza (tNIV) Phase 3 trial

流感（tNIV）第三阶段试验

。

The study showed that the CIC and flu vaccine candidates induced immune responses similar to those of licensed comparators Nuvaxovid and

研究表明，CIC和流感疫苗候选品诱导的免疫反应与已获许可的对照疫苗Nuvaxovid相似。

Sanofi SA’s

赛诺菲股份有限公司

SNY

索尼

Fluzone HD, respectively

Fluzone HD，分别

。

Both standalone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline).

独立的流感疫苗和CIC疫苗候选者都对疫苗株诱导了强烈的免疫反应（比基线高2.4至5.7倍）。

Also Read:

另请阅读：

Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For ‘Healthy’ Pregnant Women, Children

罗伯特·F·肯尼迪 Jr. 表示 CDC 停止为“健康”的孕妇和儿童接种新冠疫苗

“Both our combination and standalone flu vaccine candidates induced robust immune responses and were well tolerated,” said

“我们的联合疫苗和单独的流感疫苗候选产品都引发了强烈的免疫反应，并且耐受性良好，”

Ruxandra Draghia-Akli

鲁桑德拉·德拉吉亚-阿克利

, executive vice president and head of Research and Development at Novavax.

，诺瓦瓦克斯医药公司的执行副总裁兼研发部门负责人。

“This data set adds to findings from our Phase 2 trial and will help inform discussions with potential partners.”

“该数据集补充了我们第二阶段试验的发现，并将有助于为与潜在合作伙伴的讨论提供信息。”

Both vaccine candidates were well tolerated and saw reactogenicity comparable to authorized comparators.

两种疫苗候选品均具有良好的耐受性，其反应原性与已授权的对照物相当。

Nearly all (>98%) solicited adverse events were mild or moderate in severity.

几乎所有（>98%）的征集性不良事件均为轻度或中度严重程度。

The cohort was designed to provide descriptive data on three flu strains (H1N1, H3N2, B) and SARS-CoV-2 (COVID-19) to inform a future registrational Phase 3 program.

该队列旨在提供关于三种流感病毒株（H1N1、H3N2、B型）和SARS-CoV-2（COVID-19）的描述性数据，以为未来的注册性III期项目提供信息。

The descriptive trial evaluated the safety and immunogenicity of the CIC and standalone flu vaccine candidates compared to Nuvaxovid and Fluzone HD in approximately 2,000 adults aged 65 and older.

该描述性试验评估了CIC和单独的流感疫苗候选药物在约2000名65岁及以上的成年人中的安全性和免疫原性，并与Nuvaxovid和Fluzone HD进行了比较。

This trial was not adequately powered to demonstrate statistical significance.

该试验未能充分证明统计学意义。

In May 2023, Novavax unveiled data for its COVID-influenza combination vaccine and

2023年5月，诺瓦瓦克斯公司公布了其新冠-流感联合疫苗的数据并

two other shots

两外两枪

。

Data from a Phase 2 trial in adults aged 50-80 showed that the combination shot produced an immune response comparable to its protein-based COVID vaccine and already approved influenza shots.

一项针对50至80岁成年人的二期试验数据显示，这种组合疫苗产生的免疫反应与其基于蛋白质的新冠疫苗以及已获批的流感疫苗相当。

The study found that all three of Novavax’s vaccine candidates—the COVID/flu combination shot, a standalone flu shot, and a higher dose of its COVID shot—were safe and well-tolerated.

研究发现，诺瓦瓦克斯的三种候选疫苗——新冠/流感联合疫苗、单独的流感疫苗以及更高剂量的新冠疫苗——都是安全且耐受性良好的。

In May, Novavax received limited approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, Nuvaxovid. This marked a regulatory milestone and unlocking a $175 million milestone payment

今年 5 月，诺瓦瓦克斯从美国食品药品监督管理局 (FDA) 获得了对其新冠疫苗 Nuvaxovid 的有限批准。这标志着一个监管里程碑，并解锁了 1.75 亿美元的里程碑付款。

from partner Sanofi

来自合作伙伴赛诺菲

。

Earlier in June, the FDA approved

早在六月，FDA就批准了

Moderna, Inc.'s

莫德纳公司

MRNA

信使核糖核酸

mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease

mNexspike（mRNA-1283）是一种新的新冠疫苗，适用于65岁及以上的所有成年人，以及12至64岁且具有一种或多种由疾病控制中心定义的基础风险因素的人群。

Control and Prevention (CDC)

控制与预防中心 (CDC)

。

Price Action:

价格走势:

NVAX stock is up 0.56% at $7.24 at the last check on Wednesday.

NVAX股票在周三的最后一次检查中上涨了0.56%，达到7.24美元。

加载中...